Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Read more about Ultimovacs
Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.
We will provide universally accessible solutions.
Ultimovacs held its presentation of the company’s Q3-19 report on 14 November 2019 at Oslo Cancer Cluster Innovation Park. The presentation was recorded and can be viewed on our webcast
The report and presentation is available in the “Reports and presentation” section.
Poster presented on 9 November at the 2019 Annual Meeting of Society for Immunotherapy of Cancer (SITC). The poster is available in the “Reports and Presentations”-section.
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.